- Verseon said it had presented its lead oral drug candidates at a conference in Philadelphia.

The company said it was developing the first oral medication for diabetic macular edema.

Its drug candidates could become an alternative to eye injections, the current standard of care for millions of diabetics at risk of vision loss.

They were presented at this week's 2019 BIO International Convention in Philadelphia.

At 8:51am: [LON:VERS] share price was 0p at 49.3p

Story provided by